Francesco Granata, M.D. Joins Board of Prismic Pharmaceuticals

        Francesco Granata, M.D. Joins Board of Prismic Pharmaceuticals

PR Newswire

SCOTTSDALE, Ariz., Dec. 3, 2013

SCOTTSDALE, Ariz., Dec. 3, 2013 /PRNewswire/ --Prismic Pharmaceuticals, Inc.,
a Scottsdale, Arizona-based, commercial-stage pharmaceutical company focused
on prescription Medical Foods, today announced the election of Francesco
Granata, M.D., to its Board of Directors.

Dr. Granata is currently Executive in Residence at Warburg Pincus, a leading
private equity firm focused on growth investing. He is an accomplished
healthcare executive with more than 35 years of experience in the
international pharmaceutical and biotechnology industries. Before joining
Warburg Pincus, Dr. Granata held senior management positions at Pfizer, where
he was President of the Northern Europe region; Schering-Plough, where he
served as Group Vice President and President for the Europe and Canada region;
and most recently at Biogen Idec Inc., where he was Executive Vice President
of Global Commercial Operations, with responsibilityfor worldwide Commercial
Operations and Medical Affairs. Dr. Granata is also a Board Member of
Circassia, a UK-based specialty Biopharmaceutical company and Italfarmaco, one
of Italy's leading international pharmaceutical groups.

"Francesco Granata has had an exceptionally successful career and brings a
wealth of healthcare experience and strategic vision to our Board of
Directors," commented Peter Moriarty, Chairman and CEO of Prismic. "Prior to
joining the pharmaceutical industry, Francesco practiced as a physician and
surgeon, specializing in Cardiology. He has also been Chairman of the
European Committee of the Pharmaceutical Research and Manufacturers
Association of America and Co-Chairman of the Heads of Europe Committee of the
European Federation of Pharmaceutical Industries and Associations. We are
honored that he has accepted the invitation to join our Board. We are
confident of the contribution he will make in helping the Board to guide
Prismic's continuing path to commercial success and increased value for our
shareholders."

"Prismic has an extremely interesting and innovative portfolio of
patent-protected products," stated Dr. Granata. "I believe that the company
has identified products and market opportunities that are medically important
as well as commercially very attractive. Prismic has the choice of exploiting
those opportunities alone or in partnership with other commercial entities in
the United States and Internationally. I look forward to working with my
fellow Board members to help Management drive optimum value for our
shareholders."

About Prismic Pharmaceuticals, Inc.
Prismic Pharmaceuticals, Inc., is a privately held, commercial-stage
pharmaceutical company focused on the development and marketing of
prescription Medical Foods for the clinical dietary management of the
metabolic processes associated with many of the disorders associated with the
aging population, particularly where inflammation is involved. The company,
founded in 2011, is headquartered in Scottsdale, Arizona, with offices in
Boston, USA, and London, England. Contact 480.422.1810 or visit
www.PrismicPharma.com.

INFORMATION CONTACT
Peter Moriarty
Tel: 480.422.1810

SOURCE Prismic Pharmaceuticals, Inc.

Website: http://www.prismicpharma.com
 
Press spacebar to pause and continue. Press esc to stop.